Effect of sarcosine on antioxidant parameters and metallothionein content in the PC-3 prostate cancer cell line

Cernei,Natalia; Zitka,Ondrej; Skalickova,Sylvie; Gumulec,Jaromir; Sztalmachova,Marketa; Rodrigo,Miguel  Angel Merlos; Sochor,Jiri; Masarik,Michal; Adam,Vojtech; Hubalek,Jaromir; Trnkova,Libuse; Kruseova,Jarmila; Eckschlager,Tomas; Kizek,Rene

doi:10.3892/or.2013.2389

Effect of sarcosine on antioxidant parameters and metallothionein content in the PC-3 prostate cancer cell line

Authors:
- Natalia Cernei
- Ondrej Zitka
- Sylvie Skalickova
- Jaromir Gumulec
- Marketa Sztalmachova
- Miguel Angel Merlos Rodrigo
- Jiri Sochor
- Michal Masarik
- Vojtech Adam
- Jaromir Hubalek
- Libuse Trnkova
- Jarmila Kruseova
- Tomas Eckschlager
- Rene Kizek
View Affiliations

Affiliations: Department of Chemistry and Biochemistry, Faculty of Agronomy, Mendel University in Brno, CZ-613 00 Brno, Czech Republic, Department of Paediatric Haematology and Oncology, Second Faculty of Medicine, Charles University in Prague and University Hospital Motol, CZ-150 06 Prague 5, Czech Republic
Published online on: April 8, 2013 https://doi.org/10.3892/or.2013.2389
Pages: 2459-2466

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Sarcosine is currently one of the most discussed markers of prostate cancer. It is involved in amino acid metabolism and methylation processes that occur during the progression of prostate cancer. In this study, we monitored the effect of the addition of sarcosine (0; 10; 250; 500; 1,000 and 1,500 µM) in a time-dependent manner (0-72 h) on the PC-3 prostate cancer cell line. For the assessment of cell viability, the commonly used MTT test was employed. Furthermore, ion-exchange liquid chromatography was used for the determination of sarcosine content in the PC-3 cells. We also determined metallothionein (MT) levels by chip capillary electrophoresis and Brdicka reaction in the cells treated with sarcosine. Sarcosine levels in the cells increased in a concentration-dependent manner levels increased from only 270 nM with the lowest applied concentration of sarcosine (10 µM) to 106 µM with the highest applied concentration of sarcosine (1,500 µM). There was a marginal change observed in the MT concentration. Finally, the antioxidant activity of the PC-3 cells was determined using five different spectrophotometric methods [2,2-diphenyl-1-picrylhydrazyl (DPPH), ferric reducing ability of plasma (FRAP), free radicals, N,N-dimethyl-p-phenylenediamine (DMPD) and 2,2'-azino-bis(3-ethylbenzothiazoline-6-sulphonic acid (ABTS)]. A significant negative correlation was observed between DPPH and FRAP (r=-0.68 at p<0.001) and between DMPD and ABST (r=-0.64 at p<0.001). Additionally, as regards the correlation between MT and DPPH, a significant positive trend (r=0.62 at p<0.001) was observed.

View Figures

View References

1	Boyd LK, Mao XY, Xue LY, et al: High-resolution genome-wide copy-number analysis suggests a monoclonal origin of multifocal prostate cancer. Gene Chromosomes Cancer. 51:579–589. 2012. View Article : Google Scholar : PubMed/NCBI
2	Shimojo H, Kobayashi M, Kamigaito T, Shimojo Y, Fukuda M and Nakayama J: Reduced glycosylation of alpha-dystroglycans on carcinoma cells contributes to formation of highly infiltrative histological patterns in prostate cancer. Prostate. 71:1151–1157. 2011. View Article : Google Scholar
3	Chang HH, Chen BY, Wu CY, et al: Hedgehog overexpression leads to the formation of prostate cancer stem cells with metastatic property irrespective of androgen receptor expression in the mouse model. J Biomed Sci. 18:62011. View Article : Google Scholar
4	Song LM, Zhu YC, Han P, et al: A retrospective study: correlation of histologic inflammation in biopsy specimens of Chinese men undergoing surgery for benign prostatic hyperplasia with serum prostate-specific antigen. Urology. 77:688–692. 2011. View Article : Google Scholar
5	Astigueta JC, Abad MA, Morante C, Pow-Sang MR, Destefano V and Montes J: Characteristics of metastatic prostate cancer ocurring in patients under 50 years of age. Actas Urol Esp. 34:327–332. 2010.(In Spanish).
6	Lindstrom S, Schumacher FR, Cox D, et al: Common genetic variants in prostate cancer risk prediction - results from the NCI Breast and Prostate Cancer Cohort Consortium (BPC3). Cancer Epidemiol Biomarkers Prev. 21:437–444. 2012. View Article : Google Scholar : PubMed/NCBI
7	Hall MJ, Ruth K and Giri VN: Rates and predictors of colorectal cancer screening by race among motivated men participating in a prostate cancer risk assessment program. Cancer. 118:478–484. 2012. View Article : Google Scholar : PubMed/NCBI
8	Vindrieux D, Reveiller M, Chantepie J, et al: Down-regulation of DcR2 sensitizes androgen-dependent prostate cancer LNCaP cells to TRAIL-induced apoptosis. Cancer Cell Int. 11:422012. View Article : Google Scholar : PubMed/NCBI
9	Paquet S, Fazli L, Grosse L, et al: Differential expression of the androgen-conjugating UGT2B15 and UGT2B17 enzymes in prostate tumor cells during cancer progression. J Clin Endocrinol Metab. 97:E428–E432. 2012. View Article : Google Scholar : PubMed/NCBI
10	Armstrong AJ, Eisenberger MA, Halabi S, et al: Biomarkers in the management and treatment of men with metastatic castration-resistant prostate cancer. Eur Urol. 61:549–559. 2012. View Article : Google Scholar : PubMed/NCBI
11	Prensner JR, Rubin MA, Wei JT and Chinnaiyan AM: Beyond PSA: the next generation of prostate cancer biomarkers. Sci Transl Med. 4:127rv32012. View Article : Google Scholar : PubMed/NCBI
12	Lattanzi J, McNeely S, Hanlon A, Das I, Schultheiss TE and Hanks GE: Daily CT localization for correcting portal errors in the treatment of prostate cancer. Int J Radiat Oncol Biol Phys. 41:1079–1086. 1998. View Article : Google Scholar : PubMed/NCBI
13	van Vugt HA, Roobol MJ, Busstra M, et al: Compliance with biopsy recommendations of a prostate cancer risk calculator. BJU Int. 109:1480–1488. 2012.PubMed/NCBI
14	Schoder H and Larson SM: Positron emission tomography for prostate, bladder, and renal cancer. Semin Nucl Med. 34:274–292. 2004. View Article : Google Scholar : PubMed/NCBI
15	Fukushima K, Satoh T, Baba S and Yamashita K: alpha 1,2-Fucosylated and beta-N-acetylgalactosaminylated prostate-specific antigen as an efficient marker of prostatic cancer. Glycobiology. 20:452–460. 2010. View Article : Google Scholar : PubMed/NCBI
16	Page ST, Hirano L, Gilchriest J, et al: Dutasteride reduces prostate size and prostate specific antigen in older hypogonadal men with benign prostatic hyperplasia undergoing testosterone replacement therapy. J Urol. 186:191–197. 2011. View Article : Google Scholar
17	Luo J, Zha S, Gage WR, et al: Alpha-methylacyl-CoA racemase: a new molecular marker for prostate cancer. Cancer Res. 62:2220–2226. 2002.PubMed/NCBI
18	Cao DL, Ye DW, Zhang HL, Zhu Y, Wang YX and Yao XD: A multiplex model of combining gene-based, protein-based, and metabolite-based with positive and negative markers in urine for the early diagnosis of prostate cancer. Prostate. 71:700–710. 2011. View Article : Google Scholar : PubMed/NCBI
19	Sreekumar A, Poisson LM, Rajendiran TM, et al: Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature. 457:910–914. 2009. View Article : Google Scholar : PubMed/NCBI
20	Dahl M, Bouchelouche P, Kramer-Marek G, Capala J, Nordling J and Bouchelouche K: Sarcosine induces increase in HER2/neu expression in androgen-dependent prostate cancer cells. Mol Biol Rep. 38:4237–4243. 2011. View Article : Google Scholar : PubMed/NCBI
21	Sochor J, Ryvolova M, Krystofova O, et al: Fully automated spectrometric protocols for determination of antioxidant activity: advantages and disadvantages. Molecules. 15:8618–8640. 2010. View Article : Google Scholar : PubMed/NCBI
22	Sochor J, Salas P, Zehnalek J, et al: An assay for spectrometric determination of antioxidant activity of a biological extract. Listy Cukrov Reparske. 126:416–417. 2010.
23	Pohanka M, Sochor J, Ruttkay-Nedecky B, et al: Automated assay of the potency of natural antioxidants using pipetting robot and spectrophotometry. J Appl Biomed. 10:155–167. 2012. View Article : Google Scholar
24	Ghosh A, Wang YN, Klein E and Heston WD: Novel role of prostate-specific membrane antigen in suppressing prostate cancer invasiveness. Cancer Res. 65:727–731. 2005.PubMed/NCBI
25	Tai S, Sun Y, Squires JM, et al: PC3 is a cell line characteristic of prostatic small cell carcinoma. Prostate. 71:1668–1679. 2011. View Article : Google Scholar : PubMed/NCBI
26	Moolenaar SH, Poggi-Bach J, Engelke UF, et al: Defect in dimethylglycine dehydrogenase, a new inborn error of metabolism: NMR spectroscopy study. Clin Chem. 45:459–464. 1999.PubMed/NCBI
27	Cernei N, Zitka O, Ryvolova M, et al: Spectrometric and electrochemical analysis of sarcosine as a potential prostate carcinoma marker. Int J Electrochem Sci. 7:4286–4301. 2012.
28	Eckschlager T, Adam V, Hrabeta J, Figova K and Kizek R: Metallothioneins and cancer. Curr Protein Pept Sci. 10:360–375. 2009. View Article : Google Scholar : PubMed/NCBI
29	Krizkova S, Fabrik I, Adam V, Hrabeta J, Eckschlager T and Kizek R: Metallothionein - a promising tool for cancer diagnostics. Bratisl Lek Listy. 110:93–97. 2009.PubMed/NCBI
30	Krizkova S, Adam V, Eckschlager T and Kizek R: Easy-to-use and rapid detection of potential tumour disease marker metallothionein by using of PVDF membranes and chicken antibodies. FEBS J. 276:317. 2009.
31	Krizkova S, Fabrik I, Huska D, et al: An adsorptive transfer technique coupled with Brdicka reaction to reveal the importance of metallothionein in chemotherapy with platinum based cytostatics. Int J Mol Sci. 11:4826–4842. 2010. View Article : Google Scholar : PubMed/NCBI
32	Krizkova S, Masarik M, Majzlik P, et al: Serum metallothionein in newly diagnosed patients with childhood solid tumours. Acta Biochim Pol. 57:561–566. 2010.PubMed/NCBI
33	Krejcova L, Fabrik I, Hynek D, et al: Metallothionein electrochemically determined using Brdicka reaction as a promising blood marker of head and neck malignant tumours. Int J Electrochem Sci. 7:1767–1784. 2012.
34	Sochor J, Hynek D, Krejcova L, et al: Study of metallothionein role in spinocellular carcinoma tissues of head and neck tumours using Brdicka reaction. Int J Electrochem Sci. 7:2136–2152. 2012.
35	Gumulec J, Masarik M, Krizkova S, et al: Evaluation of alpha-methylacyl-CoA racemase, metallothionein and prostate specific antigen as prostate cancer prognostic markers. Neoplasma. 59:191–201. 2012. View Article : Google Scholar : PubMed/NCBI
36	Krizkova S, Ryvolova M, Gumulec J, et al: Electrophoretic fingerprint metallothionein analysis as a potential prostate cancer biomarker. Electrophoresis. 32:1952–1961. 2011. View Article : Google Scholar : PubMed/NCBI
37	Hamer DH: Metallothionein. Annu Rev Biochem. 55:913–951. 1986. View Article : Google Scholar : PubMed/NCBI
38	Krizkova S, Adam V and Kizek R: Study of metallothionein oxidation by using of chip CE. Electrophoresis. 30:4029–4033. 2009. View Article : Google Scholar : PubMed/NCBI
39	Krizkova S, Masarik M, Eckschlager T, Adam V and Kizek R: Effects of redox conditions and zinc(II) ions on metallothionein aggregation revealed by chip capillary electrophoresis. J Chromatogr A. 1217:7966–7971. 2010. View Article : Google Scholar : PubMed/NCBI
40	Adam V, Fabrik I, Eckschlager T, Stiborova M, Trnkova L and Kizek R: Vertebrate metallothioneins as target molecules for analytical techniques. TrAC Trends Anal Chem. 29:409–418. 2010. View Article : Google Scholar
41	Ryvolova M, Krizkova S, Adam V, et al: Analytical methods for metallothionein detection. Curr Anal Chem. 7:243–261. 2011.
42	Sochor J, Pohanka M, Ruttkay-Nedecky B, et al: Effect of selenium in organic and inorganic form on liver, kidney, brain and muscle of Wistar rats. Cent Eur J Chem. 10:1442–1451. 2012. View Article : Google Scholar
43	Jurikova T, Sochor J, Rop O, et al: Evaluation of polyphenolic profile and nutritional value of non-traditional fruit species in the Czech Republic - a comparative study. Molecules. 17:8968–8981. 2012. View Article : Google Scholar : PubMed/NCBI
44	Rop O, Reznicek V, Mlcek J, et al: Antioxidant and radical oxygen species scavenging activities of 12 cultivars of blue honeysuckle fruit. Hort Sci. 38:63–70. 2011.
45	Sochor J, Babula P, Krska B, et al: Evaluation of output signals from CoulArray detector for determination of antioxidant capacity of apricots samples. Analysis of Biomedical Signals and Images. Jan J, Jirik R, Kolar R, Kolarova J, Kozumplik J and Provaznik I: Brno University of Technology VUT v Brně Press; Brno: pp. 209–214. 2010
46	Krauth-Siegel RL and Leroux AE: Low-molecular-mass antioxidants in parasites. Antioxid Redox Signal. 17:583–607. 2012. View Article : Google Scholar : PubMed/NCBI
47	Pohanka M, Karasova JZ, Musilek K, Kuca K, Jung YS and Kassa J: Changes of rat plasma total low molecular weight antioxidant level after tabun exposure and consequent treatment by acetylcholinesterase reactivators. J Enzyme Inhib Med Chem. 26:93–97. 2011. View Article : Google Scholar
48	Parejo L, Codina C, Petrakis C and Kefalas P: Evaluation of scavenging activity assessed by Co(II)/EDTA-induced luminol chemiluminescence and DPPH· (2,2-diphenyl-1-picrylhydrazyl) free radical assay. J Pharmacol Toxicol Methods. 44:507–512. 2000.PubMed/NCBI
49	Nilsson J, Pillai D, Onning G, Persson C, Nilsson A and Akesson B: Comparison of the 2,2′-azinobis-3-ethylbenzotiazoline-6-sulfonic acid (ABTS) and ferric reducing antioxidant power (FRAP) methods to asses the total antioxidant capacity in extracts of fruit and vegetables. Mol Nutr Food Res. 49:239–246. 2005.
50	Asghar MN, Khan IU, Arshad MN and Sherin L: Evaluation of antioxidant activity using an improved DMPD radical cation decolorization assay. Acta Chim Slov. 54:295–300. 2007.